Treats locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal…. Sold as Rybrevant. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Amivantamab-Vmjw (sold as Rybrevant), first approved May 21, 2021, with 5 new uses approved and 0 published complete response letters.
| Rybrevant | Part B | $151M | +115% | 1,400 |
| Rybrevant | Part D | $6.4M | +109% | 57 |
| Study | Phase | Status | Posted |
|---|---|---|---|
| Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)Lung Non-Small Cell Carcinoma · SWOG Cancer Research Network | Phase 2 | Recruiting | Nov 3, 2023 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| May 21, 2021 | RybrevantBLA 761210 · New molecular entity | Janssen Biotech | 10 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
